Dashboard
Manage Tickers

ETNB89bio, Inc.

Nasdaq 89bio.com


$ 9.47 $ 0.47 (5.22 %)    

Thursday, 29-Aug-2024 11:36:20 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.41 $ 3.70 (0.78 %)
DIA $ 414.59 $ 0.25 (0.06 %)
SPY $ 562.22 $ 2.04 (0.36 %)
TLT $ 97.37 $ -0.18 (-0.18 %)
GLD $ 233.06 $ 1.06 (0.46 %)
$ 9
$ 9.22
$ 9.39 x 100
$ 9.43 x 200
$ 8.95 - $ 9.47
$ 6.58 - $ 18.25
608,052
na
953.19M
$ 1.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-01-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 03-15-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-24-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 11-13-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-13-2020 03-31-2020 10-Q
19 03-18-2020 12-31-2019 10-K
20 12-18-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

89bio-appoints-francis-sarena-as-chief-operating-officer-effective-august-5-2024
89bio Appoints Francis Sarena As Chief Ope...
08/07/2024 12:09:03

raymond-james-maintains-strong-buy-on-89bio-raises-price-target-to-53
Raymond James Maintains Strong Buy on 89bi...
08/06/2024 17:11:17

Raymond James analyst Steven Seedhouse maintains 89bio (NASDAQ:ETNB) with a Strong Buy and raises the price target from $50 ...

rbc-capital-maintains-sector-perform-on-89bio-lowers-price-target-to-12
RBC Capital Maintains Sector Perform on 89...
08/06/2024 12:44:56

RBC Capital analyst Brian Abrahams maintains 89bio (NASDAQ:ETNB) with a Sector Perform and lowers the price target from $13 ...

hc-wainwright--co-reiterates-buy-on-89bio-maintains-29-price-target
HC Wainwright & Co. Reiterates Buy on 89bi...
08/06/2024 10:42:12

HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.

89bio-q2-eps-048-beats-057-estimate
89bio Q2 EPS $(0.48) Beats $(0.57) Estimate
08/05/2024 20:34:25

89bio (NASDAQ:ETNB) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.57) by 15.7...

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/01/2024 15:05:58

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/17/2024 17:29:54

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/12/2024 16:14:15

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

hc-wainwright--co-reiterates-buy-on-89bio-maintains-29-price-target
HC Wainwright & Co. Reiterates Buy on 89bi...
06/11/2024 10:42:58

HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.

whats-going-on-with-fattly-liver-disease-focused-madrigal-pharmaceuticals-sagimet-biosciences-shares-on-wednesday
What's Going On With Fattly Liver Disease ...
06/05/2024 19:17:50

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress ...

89bio-will-present-48-week-data-from-enliven-phase-2b-pegozafermin-trial-in-mash-at-easl-international-liver-congress
89bio Will Present 48-Week Data From ENLIV...
05/22/2024 20:22:47

89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innov...

cantor-fitzgerald-reiterates-overweight-on-89bio-maintains-29-price-target
Cantor Fitzgerald Reiterates Overweight on...
05/17/2024 13:49:16

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.

hc-wainwright--co-reiterates-buy-on-89bio-maintains-29-price-target
HC Wainwright & Co. Reiterates Buy on 89bi...
05/17/2024 12:13:50

HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.

hc-wainwright--co-reiterates-buy-on-89bio-maintains-29-price-target
HC Wainwright & Co. Reiterates Buy on 89bi...
05/16/2024 10:56:31

HC Wainwright & Co. analyst Ed Arce reiterates 89bio (NASDAQ:ETNB) with a Buy and maintains $29 price target.

evercore-isi-group-maintains-outperform-on-89bio-lowers-price-target-to-33
Evercore ISI Group Maintains Outperform on...
05/15/2024 13:19:59

Evercore ISI Group analyst Liisa Bayko maintains 89bio (NASDAQ:ETNB) with a Outperform and lowers the price target from $37 ...

89bio-initiates-phase-3-enlighten-cirrhosis-trial-of-pegozafermin-in-mash-patients-with-compensated-cirrhosis
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosi...
05/14/2024 12:08:43

hc-wainwright--co-maintains-buy-on-89bio-lowers-price-target-to-29
HC Wainwright & Co. Maintains Buy on 89bio...
05/10/2024 12:09:58

HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and lowers the price target from $31 to $29.

89bio-q1-2024-gaap-eps-054-misses-046-estimate
89bio Q1 2024 GAAP EPS $(0.54) Misses $(0....
05/09/2024 21:28:46

89bio (NASDAQ:ETNB) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.46) by 17...

b-of-a-securities-assumes-89bio-at-buy-announces-price-target-of-30
B of A Securities Assumes 89bio at Buy, An...
04/22/2024 10:14:26

B of A Securities analyst Alexandria Hammond assumes 89bio (NASDAQ:ETNB) with a Buy rating and announces Price Target of $30.

on-april-4-2024-89bio-entered-into-collaboration-agreement-with-bibo-biopharma-engineering---filing
On April 4, 2024, 89Bio Entered Into Colla...
04/10/2024 20:35:46

BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION